Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that it will deliver a poster presentation at the 53rd Annual Meeting of ASH, the American Society of Hematology. The conference will be held December 10-13 th, 2011 at the San Diego Convention Center in San Diego, California. The Company will present during the Oral and Poster Abstracts Program that will begin Saturday December 10 th, at 5:30 p.m. Pacific Time. The poster presentation, entitled “ Pharmacodynamic, Biodistribution and Toxicology Results for SNS01-T, a Nanoparticle That Targets eIF5A for the Treatment of Multiple Myeloma”, will describe the characteristics of SNS01-T, which is the subject of an on-going clinical study at the Mayo Clinic. The poster will be presented by Catherine Taylor, Research Associate from Senesco CSO John Thompson’s research laboratory at the University of Waterloo in Ontario, Canada. Additional details about the conference can be found at:

About Multiple Myeloma

Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies. Malignant plasma cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal white blood cells. Median survival time from first treatment is 2½ to 5 years depending on disease stage at diagnosis. In the United States there are almost 20,000 newly diagnosed cases of multiple myeloma annually and a total of approximately 65,000 patients with the disease. Senesco was previously granted orphan drug status for SNS01-T, the Company’s lead drug candidate for treatment of multiple myeloma.

About Senesco Technologies, Inc.

Senesco Technologies is leveraging proprietary technology that regulates programmed cell death, or apoptosis. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications treating certain inflammatory and ischemic diseases. The Company has initiated a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners’ products.

If you liked this article you might like

Nursing Homes Cry All the Way to the Bank